DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 4,684,635 Orentreich Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 4,684,635 Orentreich Et Al United States Patent (19) 11 Patent Number: 4,684,635 Orentreich et al. (45) Date of Patent: Aug. 4, 1987 54: COMPOSITIONS AND METHODS FOR N. Orentreich et al., "Biology of Scaly Hair Growth," INHIBITING THE ACTION OF ANDROGENS 9 Clinics in Plastic Surgery (1982), 197-205. R. Aron-Brunetiere, "Aspects of Endocrinological 75 Inventors: Norman Orentreich, 140 E. 72, New Treatment," Hair Research (1981), 312-317. York, N.Y. 10021; Jonathan R. J. R. Rentoul, "Management of the Hirsuite Woman," Matias, Richmond Hill, N.Y. 22 Int'l J. of Derm. (1983), 265-272. 73) Assignee: Norman Orentreich, New York, N.Y. P. G. Nielsen, "Treatment of Moderate Idiopathic Hir sutism,' 165 Dermatologica (1982), 636-639. 21) Appl. No.: 846,498 F. Neuman et al., "Central Actions of Antiandrogens,' Androgens and Antiandrogens (1977), 163-177. 22 Filed: Mar. 27, 1986 F. J. Ebling, "Antiandrogens and Dermatology,” An drogens and Antiandrogens (1977), 341-349. Related U.S. Application Data W. I. P. Mainwaring, “Modes of Action of Antiandro I63) Continuation of Ser. No. 609,152, May 11, 1984, aban gens,' Androgens and Antiandrogens (1977), 151-161. doned. J. P. Raynaud et al., "Present Trends in Antiandrogen 51) Int. Cl............................................... A61K 31/56 Research,” Androgens and Antiandrogens (1977), 52 U.S. Cl. .................................... 514/170; 514/171; 28-293. 514/175; 514/177; 514/178 A. L. Southren et al., "Effect of Progestagens,' Andro 58) Field of Search ............... 514/177, 178, 170, 171, gens and Antiandrogens (1977), 267-279. 514/175 Primary Examiner-Leonard Schenkman Attorney, Agent, or Firm-Panitch Schwarze Jacobs and (56) References Cited Nadel U.S. PATENT DOCUMENTS 57 ABSTRACT 4,347,245 8/1982 Shapiro ............................... 424/24 Synergistic compositions for inhibiting the action of OTHER PUBLICATIONS androgens comprise the combination in a single topical preparation of a 5a-reductase enzyme inhibitor and an Federal Register, vol. 45-No. 218 (1980), pp. androgen receptor blocking agent in a pharmaceutically 73955-73960. and dermatologically acceptable vehicle. The composi Federal Register, vol. 50, No. 10 (1985), pp. 2190-2198. tions may be topically applied to affected areas of the J. S. Strauss, "Hormones and the Pilosebaceous Appa skin in the treatment or prevention of sebaceous gland ratus,” Hair Research (1981), 223-228. hypertrophy, hirsutism and male-pattern baldness in A. Schleusener et al., "Pharmacology of Old and New mammals. The inhibitor and blocking agent are present Antiandrogens,' Androgens and Anti-Androgen Therapy in the composition in a weight ratio of about 1:20 to 5:1, (1981), 71-93. with the inhibitor comprising up to about 0.1% w/v of J. M. Beazley et al., "Skin Metabolism,' Androgens and the composition and the blocking agent comprising up Anti-Androgen Therapy (1982), 41-69. to about 1% w/v of the composition. J. Girard et al., "Inhibition of Testosterone Metabo lism' 269 Arch Dermatol. Res. (1981), 281-290. 12 Claims, No Drawings 4,684,635 1. 2 The steroid combinations may be delivered through the COMPOSITIONS AND METHODS FOR skin by means of various topical vehicles. INHIBITING THE ACTION OF ANDROGENS DETAILED DESCRIPTION OF THE This is a continuation of Ser. No. 609,152, filed May 5 PREFERRED EMBODIMENT 11, 1984, now abandoned. There are a number of steroids, steroid precursors and derivatives which are known to be effective as FIELD OF THE INVENTION 5a-reductase inhibitors and which may be used in the The present invention relates to compositions and compositions of the present invention. These include methods for inhibiting the action of androgens. More 10 progesterone, 17a-carboxylic acid derivatives of testos particularly, the invention is directed to synergistic terone, desoxycorticosterone, desoxycorticosterone combinations of a 5a-reductase enzyme inhibitor and an acetate, 19-nor-testosterone, 4-pregnen-20p8-ol-3-one androgen receptor blocking agent for topical applica and 17a-hydroxyprogesterone. Of these, progesterone tions to the skin in the treatment and prevention of is preferred since it is the most active inhibitor and has sebaceous gland hypertrophy, hirsutism and male-pat 5 been shown to be topically effective by itself. tern baldness. Both steroidal and non-steroidal androgen receptor blocking agents (blockers or inhibitors) may be used in BACKGROUND OF THE INVENTION the synergistic compositions of the present invention. The development of acne, hirsutism and male-pattern Representative examples of steroidal blocking agents baldness is dependent upon the presence of androgens, 20 include spironolactone, cyproterone acetate, trimethyl particularly testosterone and dihydrotestosterone trienolone (available from Roussel Uclaf under the des (DHT). Testosterone is secreted into the blood stream ignation RU 2956), canrenone and canrenoic acid. Ex by the adrenals and gonads and enters the cells of the amples of suitable non-steroidal blocking agents include sebaceous glands or hair follicles. This steroid binds flutamide (a,a,a-trifluoro-2-methyl-4'-nitro-m-pro specifically to the 5a-reductase enzyme which converts 25 pionotoluidide) and hydroxy-flutamide (a,a,a-tri testosterone to its most active metabolite DHT. DHT fluoro-2-methyl-4'-nitro-m-lactoluidide), both available binds to specific receptor proteins in the cell cytoplasm, from Schering Corp., and RU 23908 (5,5-dimethyl-3-4- and this steroid-protein complex is translocated to the nitro-3(trifluoromethyl)phenyl)-2,4-imidazolidinedione) nucleus of the cell where DHT becomes bound to the and RU 22930 (5,6-dihydro-2-methyl-4-4-nitro-3-(tri nuclear receptor protein. Nuclear binding is followed 30 fluromethyl)phenyl-2H-1,2,4-oxadiozin-3-(4H)-one), by the synthesis of specific classes of proteins, eventu available from Roussel Uclaf. ally leading to hypertrichosis (hirsutism), alopecia Generally, the ratios of 5a-reductase inhibitor to (male-pattern baldness) or sebaceous gland hypertrophy androgen receptor blocking agent which have been (manifested as acne or other skin inflammations), found to be effective in the compositions of the present The inhibition of testosterone conversion to DHT by 35 invention range between about 1:20 and 5:1. Ratios of the 5a-reductase enzyme and the inhibition of DHT about 1:1 to 2:1 are preferred. binding to the receptor protein are accepted therapeutic It has also been found that the synergistic effects of modalities. A number of compounds, called antiandro the combinations of the present invention are most pro gens, have been developed which can interfere with nounced at relatively low concentrations of the 5a either testosterone metabolism or DHT binding to the 40 reductase inhibitor and androgen recéptor blocker. In receptor. particular, optimal concentrations for the 5a-reductase The serious side effects (such as decreased libido) inhibitors appear to range from about 0.005% to 0.1% produced by the systemic administration of antiandro weight/volume of the total composition, while optimal gens preclude the systemic use of these drugs for the concentrations for the androgen receptor blockers ap treatment of the above skin disorders. For example, 45 pear to range from about 0.01% to 0.5% weight progesterone is a highly active 5a-reductase enzyme /volume of the total composition. Concentrations inhibitor, but systemically disturbs the menstrual cycle below about 0.005 5a-reductase inhibitor and about 0.01 in women, since it must be used on a regular basis in androgen receptor blocker give very little antiandro order to be effective. Many studies have shown that genic response. Concentrations above about 0.1% 5a individual antiandrogens can be used topically to inhibit 50 reductase inhibitor and about 0.5% androgen receptor the action of androgens. However, applicants are not blocker are not only unnecessarily wasteful, expensive aware of any prior studies on the effectiveness of com and liable to produce adverse side effects, but were also bining 5a-reductase inhibitors with androgen receptor found to have very little synergistic effect above that blocking agents in a topical preparation. obtained by applying either the 5a-reductase inhibitor 55 or the androgen receptor blocker alone. BRIEF SUMMARY OF THE INVENTION It has been found according to the present invention It has been discovered that certain combinations of a that when a 5a-reductase inhibitor is applied together 5a-reductase enzyme inhibitor and an androgen recep with an androgen receptor blocker as a single topical tor blocking agent have a synergistic effect in the inhibi preparation, the resulting inhibition of androgens was tion of the action of androgens particularly in the treat greater than the sum total of the effects produced inde ment and prevention of sebaceous gland hypertrophy, pendently by the 5a-reductase inhibitor and the andro hirsutism and male-pattern baldness. The compositions gen receptor blocker. of the invention are applied topically to affected areas These effects will now be demonstrated and de of the skin of humans and other mammals in therapeuti scribed in more detail with reference to the following cally effective amounts. These combinations of inhibi 65 specific, non-limiting examples. The hamster ear seba tors and blocking agents at certain concentrations and ceous gland was selected as a test model because of the ratios act synergistically to produce a marked inhibition similarities in morphology to human sebaceous glands of the effects of the endogenous androgens on the skin. and in cell turnover time. It is well accepted in the 4,684,635 3 4. medical literature that antiandrogens which work to The data in Table I demonstrate that each combina inhibit sebaceous glands by topical means should also tion of 5a-reductase inhibitor and androgen receptor work to inhibit the androgenic effects in the hair folli blocker produces a synergistic effect as compared to the cle. Thus, the mechanism of androgenic control is simi effects of 5a-reductase inhibitor and androgen receptor lar for sebaceous gland hypertrophy, hirsutism and blocker alone.
Load more

Recommended publications
  • Prnu-BICALUTAMIDE
    PRODUCT MONOGRAPH PrNU-BICALUTAMIDE Bicalutamide Tablets, 50 mg Non-Steroidal Antiandrogen NU-PHARM INC. DATE OF PREPARATION: 50 Mural Street, Units 1 & 2 October 16, 2009 Richmond Hill, Ontario L4B 1E4 Control#: 133521 Page 1 of 27 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 3 WARNINGS AND PRECAUTIONS....................................................................................... 4 ADVERSE REACTIONS......................................................................................................... 5 DRUG INTERACTIONS ......................................................................................................... 9 DOSAGE AND ADMINISTRATION ................................................................................... 10 OVERDOSAGE...................................................................................................................... 10 ACTION AND CLINICAL PHARMACOLOGY.................................................................. 10 STORAGE AND STABILITY............................................................................................... 11 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]
  • Context-Specific Efficacy of Apalutamide Therapy in Preclinical
    cancers Article Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer Marco A. De Velasco 1,2,* , Yurie Kura 1,2, Naomi Ando 1, Noriko Sako 1, Eri Banno 1, Kazutoshi Fujita 1, Masahiro Nozawa 1, Kazuhiro Yoshimura 1 , Kazuko Sakai 2, Kazuhiro Yoshikawa 3, Kazuto Nishio 2 and Hirotsugu Uemura 1,* 1 Department of Urology Kindai, University Faculty of Medicine, Osaka-Sayama 589-8511, Japan; [email protected] (Y.K.); [email protected] (N.A.); [email protected] (N.S.); [email protected] (E.B.); [email protected] (K.F.); [email protected] (M.N.); [email protected] (K.Y.) 2 Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan; [email protected] (K.S.); [email protected] (K.N.) 3 Research Creation Support Center, Aichi Medical University, Nagakute 480-1195, Japan; [email protected] * Correspondence: [email protected] (M.A.D.V.); [email protected] (H.U.) Simple Summary: Next-generation antiandrogens have transformed the therapeutic landscape for castration-resistant prostate cancer. Their utility in other indications, such as high-risk castration- sensitive cancers and as combination therapy, are being investigated. Our aim was to profile the in vivo antitumor activity of apalutamide in phenotypically distinct mouse models of Pten-deficient castration-naïve and castration-resistant prostate cancer, using both early- and late-stage disease Citation: De Velasco, M.A.; Kura, Y.; models, and to profile the molecular responses.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Aldactone 50 mg Film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg of Spironolactone. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet (Tablets) Round, white coloured, biconvex tablet with a peppermint odour embossed ‘SEARLE over 916’ on one side and the other side plain. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Children should only be treated under guidance of a paediatric specialist. There is limited paediatric data available (see sections 5.1 and 5.2). 4.2 Posology and method of administration Administration of Aldactone once daily with a meal is recommended. Posology Adults Congestive heart failure: Usual dose - 100 mg/day. In difficult or severe cases the dosage may be gradually increased up to 200 mg/day. When oedema is controlled, the usual maintenance level is 75 mg/day to 200 mg/day. Severe heart failure in conjunction with standard therapy (New York Heart Association Class III-IV): Based on the Randomized Aldactone Evaluation Study (RALES), treatment in conjunction with standard therapy should be initiated at a dose of spironolactone 25 mg once daily in patients with a serum potassium ≤5.0 mEq/L and serum creatinine ≤2.5 mg/dL. Patients who tolerate 25 mg once daily may have their dose increased to 50 mg once daily as clinically indicated.
    [Show full text]
  • WO 2018/111890 Al 21 June 2018 (21.06.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/111890 Al 21 June 2018 (21.06.2018) W !P O PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, C07K 16/28 (2006.01) A61K 31/4166 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 59/595 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US20 17/065841 Declarations under Rule 4.17: (22) International Filing Date: — as to applicant's entitlement to apply for and be granted a 12 December 2017 (12.12.2017) patent (Rule 4.1 7(H)) — as to the applicant's entitlement to claim the priority of the (25) Filing Language: English earlier application (Rule 4.17(Hi)) (26) Publication Langi English — of inventorship (Rule 4.1 7(iv)) (30) Priority Data: Published: 62/433,158 12 December 2016 (12.12.2016) US — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (71) Applicant (for all designated States except AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, P T RO, RS, SE, SI, SK, SM, TR): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).
    [Show full text]
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
    [Show full text]
  • Androgen Receptor Is Targeted to Distinct Subcellular Compartments in Response to Different Therapeutic Antiandrogens
    7392 Vol. 10, 7392–7401, November 1, 2004 Clinical Cancer Research Androgen Receptor Is Targeted to Distinct Subcellular Compartments in Response to Different Therapeutic Antiandrogens Hayley C. Whitaker,1 Sarah Hanrahan,3 informed sequential treatment regime may benefit prostate Nick Totty,3 Simon C. Gamble,1 cancer patients. The observed subnuclear and subcytoplas- Jonathan Waxman,1 Andrew C. B. Cato,4 mic associations of the AR suggest new areas of study to 2 1 investigate the role of the AR in the response and resistance Helen C. Hurst, and Charlotte L. Bevan of prostate cancer to antiandrogen therapy. 1Prostate Cancer Research Group and 2Cancer Research UK Molecular Oncology Unit, Department of Cancer Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom; INTRODUCTION 3Protein Analysis, Cancer Research UK, London Research Institute, Prostate cancer is the most commonly diagnosed male London, United Kingdom; and 4Forschungszentrum Karlsruhe, cancer in the United States and the second leading cause of male Institute of Toxicology and Genetics, Karlsruhe, Germany cancer death (1). Prostate growth is initially androgen depend- ent; thus, treatment involves reducing circulating androgen lev- ABSTRACT els using leuteinizing hormone-releasing hormone analogs and opposing androgen action using antiandrogens. Little is known Purpose: Antiandrogens are routinely used in the treat- about how antiandrogens elicit their effects, although they act at ment of prostate cancer. Although they are known to pre- the level of the androgen receptor (AR), which mediates the vent activation of the androgen receptor (AR), little is effects of all androgens including the major circulating androgen known about the mechanisms involved. This report repre- testosterone and the more potent dihydrotestosterone (DHT).
    [Show full text]
  • Genomic and Non-Genomic Effects of Aldosterone
    132 Current Signal Transduction Therapy, 2012, 7, 132-141 Genomic and Non-genomic Effects of Aldosterone Andrea Verhovez*, Tracy A. Williams, Silvia Monticone, Valentina Crudo, Jacopo Burrello, Maddalena Galmozzi, Michele Covella, Franco Veglio and Paolo Mulatero Department of Medicine and Experimental Oncology, Division of Internal Medicine and Hypertension, University of Torino, 10126 Torino, Italy Abstract: The last two decades have witnessed a growing number of experimental observations regarding the mineralocorticoid physiopathology, leading to a new understanding of the molecular basis of the aldosterone-induced target organ damage. As a matter of fact, although it has long been known that the combined administration of mineralocorticoids and salt leads to extensive vascular lesions in the target organs, the recognition that aldosterone is able to induce direct toxic effects on the various cell types that make up the cardiovascular organ has built up recently. Moreover, non-genomic effects have been attributed to aldosterone, i.e. effects which do not depend on the activation of the cellular transcription machinery, whose physiopathologic relevance is still being investigated. These advances in our understanding of aldosterone physiopathology have shed light on the biological reasons which are at the base of the impressive results obtained in clinical trials of aldosterone antagonism. Keywords: Aldosterone, hyperaldosteronism, endothelium. INTRODUCTION permeability by means of the generation of high electrochemical gradients. This action is performed by The hormone aldosterone was named after the aldehyde modulation of gene expression. group located on the carbon 18 of the steroidal skeleton which takes the place of the methyl group which Aldosterone synthase, the product of the CYP11B2 gene characterizes all the other steroidal compounds.
    [Show full text]
  • Australian Product Information – Aldactone® (Spironolactone)
    AUSTRALIAN PRODUCT INFORMATION – ALDACTONE® (SPIRONOLACTONE) 1. NAME OF THE MEDICINE Spironolactone 2. QUALITATIVE AND QUANTITATIVE COMPOSITION The 25 mg ALDACTONE tablets contain 25 mg spironolactone. The 100 mg ALDACTONE tablets contain 100 mg spironolactone. For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Film-coated tablets. 25 mg ALDACTONE tablets: 8.7 mm in diameter, round, biconvex, buff coloured, peppermint flavoured, film coated, stamped SEARLE over 39 on one side and unmarked on the other. 100 mg ALDACTONE tablets: 11.2 mm in diameter, round, biconvex, buff coloured, peppermint flavoured, film coated, stamped SEARLE over 134 on one side and unmarked on the other. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Essential Hypertension ALDACTONE, when used alone, is effective in lowering both systolic and diastolic blood pressure. ALDACTONE improves the hypotensive action of thiazide diuretics while at the same time reducing or preventing potassium loss due to the thiazide. ALDACTONE enhances the effectiveness of other antihypertensive agents such as beta blockers, vasodilators, etc. Version: pfpaldat10621 Supersedes: pfpaldat10220 Page 1 of 12 As adjunctive therapy in malignant hypertension. In diuretic-induced hypokalaemia when other measures are considered inappropriate or inadequate. Prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Oedematous disorders, such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver, nephrotic syndrome. Congestive Cardiac Failure ALDACTONE, when used alone, is effective in the management of oedema and sodium retention associated with congestive cardiac failure. ALDACTONE may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics.
    [Show full text]
  • Combined Oral Contraceptives Plus Spironolactone Compared With
    177:5 M Alpañés, F Álvarez-Blasco Randomized trial of common 177:5 399–408 Clinical Study and others drugs for PCOS Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial Macarena Alpañés*, Francisco Álvarez-Blasco*, Elena Fernández-Durán, Manuel Luque-Ramírez and Héctor F Escobar-Morreale Correspondence Diabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology & Nutrition, Hospital should be addressed Universitario Ramón y Cajal & Universidad de Alcalá & Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS & to H F Escobar-Morreale Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas CIBERDEM, Madrid, Spain Email *(M Alpañés and F Álvarez-Blasco contributed equally to this work) hectorfrancisco.escobar@ salud.madrid.org Abstract Objective: We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS). Design: We conducted a randomized, parallel, open-label, clinical trial comparing COC (30 μg of ethinylestradiol and 150 μg of desogestrel) plus spironolactone (100 mg/day) with metformin (850 mg b.i.d.) for one year in women with PCOS (EudraCT2008–004531–38). Methods: The composite primary outcome included efficacy (amelioration of hirsutism, androgen excess and menstrual dysfunction) and cardiometabolic safety (changes in the frequencies of disorders of glucose tolerance, dyslipidemia and hypertension). A complete anthropometric, biochemical, hormonal and metabolic evaluation was conducted every three months and data were submitted to intention-to-treat analyses. European Journal European of Endocrinology Results: Twenty-four patients were assigned to COC plus spironolactone and 22 patients to metformin.
    [Show full text]
  • Receptor Af®Nity and Potency of Non-Steroidal Antiandrogens: Translation of Preclinical ®Ndings Into Clinical Activity
    Prostate Cancer and Prostatic Diseases (1998) 1, 307±314 ß 1998 Stockton Press All rights reserved 1365±7852/98 $12.00 http://www.stockton-press.co.uk/pcan Review Receptor af®nity and potency of non-steroidal antiandrogens: translation of preclinical ®ndings into clinical activity GJCM Kolvenbag1, BJA Furr2 & GRP Blackledge3 1Medical Affairs, Zeneca Pharmaceuticals, Wilmington, DE, USA; 2Therapeutic Research Department, and 3Medical Research Department, Zeneca Pharmaceuticals, Alderley Park, Maccles®eld, Cheshire, UK The non-steroidal antiandrogens ¯utamide (Eulexin1), nilutamide (Anandron1) and bicalutamide (Casodex1) are widely used in the treatment of advanced prostate cancer, particularly in combination with castration. The naturally occurring ligand 5a-DHT has higher binding af®nity at the androgen receptor than the non-steroidal antiandrogens. Bicalutamide has an af®nity two to four times higher than 2-hydroxy¯utamide, the active metabolite of ¯utamide, and around two times higher than nilutamide for wild-type rat and human prostate androgen receptors. Animal studies have indicated that bicalutamide also exhi- bits greater potency in reducing seminal vesicle and ventral prostate weights and inhibiting prostate tumour growth than ¯utamide. Although preclinical data can give an indication of the likely clinical activity, clinical studies are required to determine effective, well-tolerated dosing regimens. As components of combined androgen blockade (CAB), controlled studies have shown survival bene®ts of ¯utamide plus a luteinising hormone-releasing hormone analogue (LHRH-A) over LHRH-A alone, and for nilutamide plus orchiectomy over orchiectomy alone. Other studies have failed to show such survival bene®ts, including those comparing ¯utamide plus orchiectomy with orchiectomy alone, and nilutamide plus LHRH-A with LHRH-A alone.
    [Show full text]
  • Topical Cyproterone Acetate Treatment in Women with Acne a Placebo-Controlled Trial
    STUDY Topical Cyproterone Acetate Treatment in Women With Acne A Placebo-Controlled Trial Doris M. Gruber, MD; Michael O. Sator, MD; Elmar A. Joura, MD; Eva Maria Kokoschka, MD; Georg Heinze, MSc; Johannes C. Huber, MD, PhD Objective: To evaluate the clinical and hormonal re- Results: After 3 months of therapy with topical cypro- sponse of topically applied cyproterone acetate, oral cy- terone acetate, the decrease of mean facial acne grade from proterone acetate, and placebo lotion in women with 1.57 to 0.67 was significantly better (P<.05) compared with acne. placebo (which showed a change from 1.57 to 1.25), but not compared with oral medication (1.56 to 0.75) (P >.05). Design: Placebo-controlled, randomized study. Lesion counts also decreased from 35.9 to 9.1 in the topi- cal cyproterone acetate group compared with oral medi- Setting: Patients were recruited from the Institute of En- cation (45.4 to 15.5) (P..05) and placebo (38.2 to 23.1) docrine Cosmetics, Vienna, Austria. (P,.05). After topical cyproterone acetate treatment, se- rum cyproterone acetate concentrations were 10 times lower Patients: Forty women with acne. than those found after oral cyproterone acetate intake. Interventions: Treatment with oral medication con- Conclusions: The therapeutic effect of topically ap- sisting of 0.035 mg of ethinyl estradiol and 2 mg of cy- plied cyproterone acetate for acne treatment was clearly proterone acetate (n=12), 20 mg of topical cyproterone demonstrated. Topically applied sexual steroids in com- acetate lotion (n=12), and placebo lotion (n=16) was of- bination with liposomes are as effective as oral antian- fered.
    [Show full text]
  • Exposure to the Antiandrogen Flutamide
    Disturbed testicular descent in the rat after prenatal exposure to the antiandrogen flutamide P. van der Schoot Department of Endocrinology and Reproduction, Faculty of Medicine and Health Sciences, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands Summary. Exposure of rats in utero to the anti-androgen flutamide resulted in feminization of the external genitalia that was noticeable at birth. This exposure also resulted in a high degree of cryptorchidism during adulthood. In most affected animals, testes were lying in 'ovary position' close to the caudal pole of the ipsilateral kidney. Cryptorchidism occurred despite normal prenatal development of the gubernacular cones and the transformation of these structures, postnatally, into muscular cremaster sacs. Inter- and intralitter variation in the response to prenatal exposure to flutamide was observed as well as intra-individual variation. Cryptorchidism frequently occurred unilaterally with right side cryptorchidism predominating. Cryptorchidism occurred in association with marked suppression of the growth of the ipsilateral epididymis and deferent duct. The possibility is considered that the poor development or absence of these structures contributes to cryptorchidism. Intra\x=req-\ individual variation supports the concept of the local nature of the influence of testis hormones in stabilization and further differentiation of the ipsilateral Wolffian duct derivatives. Cryptorchidism was enhanced when rats were treated postnatally with testosterone or oestradiol. The effect of testosterone was unexpected in view of the generally held hypothesis that androgens enhance testis descent. The effect of oestradiol was as expected: other animal models have been described in which induction of cryptorchidism by oestradiol occurs. Additional treatment with oestradiol caused further suppression of growth of the epididymis and deferent duct.
    [Show full text]